Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European standard clinical practice - Key issues for the medical care of individuals with familial leukemia.
Förster A, Davenport C, Duployez N, Erlacher M, Ferster A, Fitzgibbon J, Göhring G, Hasle H, Jongmans MC, Kolenova A, Kronnie G, Lammens T, Mecucci C, Mlynarski W, Niemeyer CM, Sole F, Szczepanski T, Waanders E, Biondi A, Wlodarski M, Schlegelberger B, Ripperger T. Förster A, et al. Among authors: niemeyer cm. Eur J Med Genet. 2023 Apr;66(4):104727. doi: 10.1016/j.ejmg.2023.104727. Epub 2023 Feb 10. Eur J Med Genet. 2023. PMID: 36775010
Rare and potentially fatal - Cytogenetically cryptic TNIP1::PDGFRB and PCM1::FGFR1 fusion leading to myeloid/lymphoid neoplasms with eosinophilia in children.
Berking AC, Flaadt T, Behrens YL, Yoshimi A, Leipold A, Holzer U, Lang P, Quintanilla-Martinez L, Schlegelberger B, Reiter A, Niemeyer C, Strahm B, Göhring G. Berking AC, et al. Cancer Genet. 2023 Apr;272-273:29-34. doi: 10.1016/j.cancergen.2023.01.002. Epub 2023 Jan 7. Cancer Genet. 2023. PMID: 36657267
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Gurnari C, Robin M, Godley LA, Drozd-Sokołowska J, Włodarski MW, Raj K, Onida F, Worel N, Ciceri F, Carbacioglu S, Kenyon M, Aljurf M, Bonfim C, Makishima H, Niemeyer C, Fenaux P, Zebisch A, Hamad N, Chalandon Y, Hellström-Lindberg E, Voso MT, Mecucci C, Duarte FB, Sebert M, Sicre de Fontbrune F, Soulier J, Shimamura A, Lindsley RC, Maciejewski JP, Calado RT, Yakoub-Agha I, McLornan DP. Gurnari C, et al. Lancet Haematol. 2023 Dec;10(12):e994-e1005. doi: 10.1016/S2352-3026(23)00265-X. Epub 2023 Oct 25. Lancet Haematol. 2023. PMID: 37898151 Review.
Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine.
Salek M, Mueller A, Alanbousi I, Cepowska Z, Dutkiewicz M, Earl J, Evseev D, Kizyma R, Kliuchkivska K, Kolodrubiec J, Matczak K, Nogovitsyna Y, Oszer A, Pogorelyy M, Raciborska A, Rasul S, Sokolowski I, Sopilnyak A, Vinitsky A, Wlodarski MW, Wobst N, Yakimkova T, Rodriguez-Galindo C, Wise PH, Mlynarski W, Agulnik A; SAFER Ukraine Collaborative. Salek M, et al. Lancet Oncol. 2023 Dec;24(12):1315-1318. doi: 10.1016/S1470-2045(23)00456-4. Lancet Oncol. 2023. PMID: 38039989 No abstract available.
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis.
Masetti R, Baccelli F, Leardini D, Gottardi F, Vendemini F, Di Gangi A, Becilli M, Lodi M, Tumino M, Vinci L, Erlacher M, Strahm B, Niemeyer CM, Locatelli F. Masetti R, et al. Among authors: niemeyer cm. Blood Adv. 2023 Aug 22;7(16):4366-4370. doi: 10.1182/bloodadvances.2023010113. Blood Adv. 2023. PMID: 37216275 Free PMC article. No abstract available.
A joint international consensus statement for measuring quality of survival for patients with childhood cancer.
van Kalsbeek RJ, Hudson MM, Mulder RL, Ehrhardt M, Green DM, Mulrooney DA, Hakkert J, den Hartogh J, Nijenhuis A, van Santen HM, Schouten-van Meeteren AYN, van Tinteren H, Verbruggen LC, Conklin HM, Jacola LM, Webster RT, Partanen M, Kollen WJW, Grootenhuis MA, Pieters R, Kremer LCM; International Childhood Cancer Outcome Project participants. van Kalsbeek RJ, et al. Nat Med. 2023 Jun;29(6):1340-1348. doi: 10.1038/s41591-023-02339-y. Epub 2023 Jun 15. Nat Med. 2023. PMID: 37322119 Review.
Azacitidine (Vidaza®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).
Rubio-San-Simón A, van Eijkelenburg NKA, Hoogendijk R, Hasle H, Niemeyer CM, Dworzak MN, Zecca M, Lopez-Yurda M, Janssen JM, Huitema ADR, van den Heuvel-Eibrink MM, Laille EJ, van Tinteren H, Zwaan CM. Rubio-San-Simón A, et al. Among authors: niemeyer cm. Paediatr Drugs. 2023 Nov;25(6):719-728. doi: 10.1007/s40272-023-00588-5. Epub 2023 Sep 11. Paediatr Drugs. 2023. PMID: 37695474 Clinical Trial.
504 results